Changes in Beneficial Ownership · 4
Certara, Inc.
CERTNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-05152026_080512.xml
Filing details
- Report period
- 2026-05-14
- Issuer
- Certara, Inc.
- Issuer CIK
- 0001827090
- Trading symbol
- CERT
Reporting owner 1
- Name
- Bedi Arjun
- Reporting owner CIK
- 0002108108
- Relationship
- Director
- Address
- C/O CERTARA, INC, 4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR, PA, 19087
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-05-14 | M · Form 4 | 5,547 | A | 0[F1] | 5,547 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | [F1] | 2026-05-14 | M · Form 4 | 5,547 | D | 0 | [F1] | [F1] | Common Stock | 5,547 | 0 | D |
| Restricted Stock Units | [F2] | 2026-05-14 | A · Form 4 | 33,222 | A | 0 | [F2] | [F2] | Common Stock | 33,222 | 33,222 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
Footnotes
- F1
- Each restricted stock unit ("RSU") was granted on February 27, 2026, under the Certara, Inc. 2020 Incentive Plan ("2020 Incentive Plan") entitling the reporting person to receive one share of the issuer's common stock per RSU. The RSUs vested and were converted to common stock on May 14, 2026, the day of the issuer's annual meeting↩ 1↩ 2↩ 3↩ 4
Signature 1
- Signed
- Daniel D. Corcoran, as Attorney-in-Fact for Arjun Bedi
- Date
- 2026-05-15
Company context
Certara transforms drug discovery and development for good, helping scientists and clinical teams generate regulatory-grade evidence faster. Its solutions combine biosimulation, clinical intelligence, and regulatory science, and are embedded in the workflows of drug developers worldwide. Certara clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies. Learn more at certara.com.
Current securities
Recent company filings
- Regulation FD DisclosureAug 7, 2026
- 10-Q filingAug 4, 2026
- Results of Operations and Financial ConditionAug 4, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 4, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJun 17, 2026